Rhumbline Advisers Invests $520,000 in Metsera Inc. $MTSR

Rhumbline Advisers bought a new stake in shares of Metsera Inc. (NASDAQ:MTSR) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 19,105 shares of the company’s stock, valued at approximately $520,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MTSR. Bank of New York Mellon Corp acquired a new stake in Metsera during the first quarter valued at approximately $884,000. New York State Common Retirement Fund acquired a new stake in Metsera during the first quarter valued at approximately $131,000. Alphabet Inc. acquired a new stake in Metsera during the first quarter valued at approximately $135,059,000. Massachusetts Financial Services Co. MA acquired a new stake in Metsera during the first quarter valued at approximately $13,111,000. Finally, Jennison Associates LLC acquired a new stake in Metsera during the first quarter valued at approximately $9,679,000.

Analysts Set New Price Targets

Several analysts recently commented on MTSR shares. Leerink Partnrs raised shares of Metsera to a “strong-buy” rating in a research note on Tuesday, September 9th. Wells Fargo & Company assumed coverage on shares of Metsera in a report on Friday, June 20th. They set an “overweight” rating and a $65.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Metsera in a report on Wednesday, September 3rd. Wall Street Zen lowered shares of Metsera from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Guggenheim boosted their price target on shares of Metsera from $56.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, June 10th. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $63.50.

Metsera Stock Performance

Shares of MTSR opened at $53.00 on Wednesday. The company’s fifty day moving average is $35.91 and its 200-day moving average is $29.52. Metsera Inc. has a 12 month low of $12.30 and a 12 month high of $54.47.

Metsera (NASDAQ:MTSR) last announced its quarterly earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.